ANDA 85755, held by Watson Labs. Liothyronine Sodium.
As of Nov 16, 2026, ANDA 85755 (Liothyronine Sodium), held by Watson Labs, was first approved by FDA on Jan 25, 1982, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 25, 1982 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Liothyronine SodiumEQ 0.025MG BASE ยท tablet;oral | Liothyronine Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters